Hilltop Medical Clinic

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes5 trials
• Obesity2 trials
• Type 1 diabetes1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Novo Nordisk A/S5 trials
• Boehringer Ingelheim1 trial

Running trials

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

  NCT07662122· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source